Products
News
Resources
Contact
Language
简体中文
繁體中文
English
日本語
한국어
Tiếng Việt
江苏苏轩堂药业有限公司 China SXT phamaceuticals
{{company.company_channel.channel_name}}
Media Room
Latest
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Follow :
X
Company Profile
Media Room
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.title}}
loading
The End
Network Errors Please Retry
{{selectname}}
{{showName}}
{{selectall}}
{{option}}
China SXT Pharmaceuticals, Inc. Adds Newly Developed Kuihuapan and Zhudanfen Advanced TCMP Products, and Announces the Expected Continuous Growth of Its Production Capacity of Luxuejin
2022-01-15 03:30
China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency
2021-12-16 21:00
China SXT Pharmaceuticals, Inc. Announces 1 for 4 Reverse Share Split
2021-02-19 21:00
China SXT Pharmaceuticals, Inc. Enters into Non-Binding LOI to Acquire Jiangsu Renji Pharmaceutical Chain Co., Ltd.
2021-02-11 21:00
NASDAQ Granted China SXT Pharmaceuticals, Inc. 180-Day Extension to Regain Compliance with Bid Price Requirement
2020-09-09 21:00
China SXT Pharmaceuticals, Inc. Announces That It Received a Grant Supported by City Government
2020-03-16 21:16
China SXT Pharmaceuticals, Inc. Announced Regulatory Approval of Its DNA Exam Laboratory
2020-01-16 21:00
China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency
2020-01-03 23:30
China SXT Pharmaceuticals, Inc. Granted to Establish Taizhou Research Center for Advanced TCMP Engineering Techniques
2019-09-11 19:00
China SXT Pharmaceuticals, Inc. Announces Filing of Annual Report on Form 20-F for Year Ended March 31, 2019
2019-08-19 20:00
China SXT Pharmaceuticals, Inc. Receives New Pharmaceutical GMP Certificate
2019-08-12 20:00
China SXT Pharmaceuticals, Inc. Announces TCM Homologous Supplements Production
2019-07-03 20:00
China SXT Pharmaceuticals, Inc. Being Admitted to Hi-tech Zone of Huangshan City in Anhui Province
2019-05-22 23:20
China SXT Pharmaceuticals, Inc. Announces Pricing of a $15 Million PIPE Financing
2019-04-17 21:01
China SXT Pharmaceuticals, Inc. Receives National High-tech Enterprise Qualification
2019-04-02 18:30
China SXT Pharmaceuticals, Inc. Announces Financial Results for the Six Months Ended September 30, 2018
2019-03-28 18:30
China SXT Pharmaceuticals, Inc. Announces Final Closing of Initial Public Offering
2019-01-04 20:30
China SXT Pharmaceuticals, Inc. Announces First Closing of Initial Public Offering
2019-01-03 02:30
China SXT Pharmaceuticals, Inc. Announces First Closing of Initial Public Offering
2019-01-03 02:30
China SXT Pharmaceuticals, Inc. Announces Effectiveness of Registration Statement on Form F-1 and Pricing the Initial Public Offering of its Ordinary Shares at $4.00 per Share
2018-09-29 05:15
1